NASDAQ$ALEC
Alector Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Alector reported a decrease in collaboration revenue and an increase in net loss for Q1 2025, while maintaining a strong cash position.
Alector, Inc. reported a net loss of $40.471 million for the three months ended March 31, 2025, compared to a net loss of $36.079 million for the same period in 2024. Collaboration revenue decreased significantly from $15.893 million in Q1 2024 to $3.674 million in Q1 2025. The company's cash, cash equivalents, and marketable securities totaled $354.6 million as of March 31, 2025, which is anticipated to provide runway into the second half of 2027.
- Collaboration revenue saw a substantial decrease, primarily due to the satisfaction of performance obligations related to the AL002 program and the latozinemab FTD-C9orf72 Phase 2 trial in Q4 2024.
- Research and development expenses decreased by $11.5 million, mainly due to a reduction in costs for the AL002 program and personnel-related costs from workforce reductions.
- The company incurred restructuring costs of $2.3 million in Q1 2025 as part of a plan to reduce its workforce by approximately 13% to align resources with strategic priorities.
- Despite the net loss, Alector maintains a strong liquidity position with $354.6 million in cash, cash equivalents, and marketable securities, projected to fund operations until the second half of 2027.
Headline financials
Revenue & EPS history
Alector · Revenue · Quarterly
$3.67M
Revenue by segment
Alector · $9.11M total across 1 segment · Q3 2023
- Collaboration Revenue$9.11M-38.7%100.0%
Forward guidance
Alector anticipates continued net losses and increased expenses as it advances product candidates through clinical development. The company expects its current cash, cash equivalents, and marketable securities to fund operations into the second half of 2027, but acknowledges the need for additional capital and the potential for delays or termination of programs if funding is insufficient.
Tailwinds
- Existing cash, cash equivalents, and marketable securities are expected to fund operations into the second half of 2027.
- Workforce reduction aligns resources with strategic priorities and advances preclinical and research pipeline.
- Strategic collaborations, such as with GSK, provide funding and expertise for product development.
- Continued investment in research and development aims to identify new product candidates and expand existing ones.
- Focus on genetically validated targets and proprietary ABC technology aims to enhance therapeutic delivery and efficacy.
Headwinds
- The company has not generated revenue from product sales and does not expect to do so in the near future.
- Significant net losses are expected to continue for the foreseeable future due to high research and development costs.
- The ability to raise additional capital is uncertain and may lead to delays, reductions, or termination of programs if not secured on favorable terms.
- Drug development is highly uncertain and involves substantial risk, with no guarantee of regulatory approval or commercial success.
- The company is highly dependent on key personnel, and failure to attract or retain qualified individuals could hinder business strategy implementation.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+1.1%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-5.5%
Avg return
30 days after
52%
15 / 29 earnings
Positive
+32.9%
Q2 2023
Best reaction
-18.4%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -16.0% | -36.6% | |
| Q4 2025 | +7.1% | -11.7% | -16.3% | |
| Q3 2025 | +4.1% | +8.4% | -2.8% | |
| Q1 2025 | +4.2% | +7.4% | +23.8% | |
| Q4 2024 | -3.5% | -15.4% | -25.0% | |
| Q3 2024 | +12.8% | +21.3% | -56.8% | |
| Q2 2024 | +0.8% | +0.9% | -4.2% | |
| Q1 2024 | -1.9% | +1.7% | -17.7% | |
| Q4 2023 | +7.9% | +14.4% | -7.1% | |
| Q3 2023 | -2.6% | -17.7% | +6.0% | |
| Q2 2023 | +32.9% | +12.4% | -15.6% | |
| Q1 2023 | +13.0% | +20.6% | +8.5% | |
| Q4 2022 | +0.9% | -9.5% | -30.3% | |
| Q3 2022 | -18.4% | +3.1% | +3.1% | |
| Q2 2022 | +16.3% | +12.7% | -6.9% | |
| Q1 2022 | -12.7% | -20.0% | -11.9% | |
| Q4 2021 | +1.9% | -1.3% | -7.8% | |
| Q3 2021 | +2.3% | +4.1% | -20.7% | |
| Q2 2021 | +9.5% | +9.0% | +10.1% | |
| Q1 2021 | -7.8% | -12.4% | +6.1% | |
| Q4 2020 | -4.7% | -10.7% | -14.3% | |
| Q3 2020 | +0.4% | +7.2% | +25.2% | |
| Q2 2020 | -6.9% | -7.4% | -13.5% | |
| Q1 2020 | -5.0% | +0.3% | +3.7% | |
| Q4 2019 | -1.5% | -4.4% | +0.8% | |
| Q3 2019 | -6.1% | -4.2% | +19.5% | |
| Q2 2019 | -1.7% | -18.0% | +9.4% | |
| Q1 2019 | +4.9% | +1.3% | +0.2% | |
| Q4 2018 | -8.6% | -3.5% | +10.8% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro